Pharmaceutical company · TAK

Takeda
clinical trial
pipeline

Registry checked

Published

Elritercept is linked to 6 distinct active studies: 6 recruiting. Vedolizumab is linked to 12 distinct active studies: 8 recruiting, 4 active but not recruiting. Zasocitinib is linked to 13 distinct active studies: 8 recruiting, 3 active but not recruiting, 2 not yet recruiting.

50 active trials lack a mapped primary therapeutic group. The categories and accepted programme links are partial enrichment, so individual study records provide additional context.

Active trial mix

Lead-sponsor scope

127active trials
as lead sponsor
  • Phase 12
  • Phase 224
  • Phase 344
  • Phase 47
  • Phase not recorded50

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

02 Oct 2026 – 31 Oct 2026 · UTC

Recorded changes

2717 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

01Primary completion

Primary completion moved later by 76 days

2026-10-02 (estimated)2026-12-17 (estimated)
02 Oct 202617 Dec 2026

A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

NCT07363720 · ClinicalTrials.gov
Recorded by ComplyRx
31 Oct 2026
Registry last updated
30 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-10-020000111
2026-10-030000221
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000221
2026-10-100000221
2026-10-110000000
2026-10-120000221
2026-10-130000111
2026-10-141020363
2026-10-150000000
2026-10-160000000
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200010122
2026-10-210000000
2026-10-221000011
2026-10-231100021
2026-10-240100011
2026-10-250000000
2026-10-260000000
2026-10-271000011
2026-10-281110031
2026-10-290000000
2026-10-300000000
2026-10-310100011
Type totals5440142717 distinct

02 / Drugs & programmes

Explore the pipeline

6 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Zasocitinib

Canonical investigational asset

13
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 26
  • Phase 37
  • Phase 40
  • Phase not recorded0
Studied condition
Crohn's Disease · Hidradenitis Suppurativa · Nonsegmental Vitiligo
Next primary completion
17 February 2027 · estimated
Open drug

Vedolizumab

entyvio · entyviopen

12
Active trials
8
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 20
  • Phase 39
  • Phase 43
  • Phase not recorded0
Studied condition
Crohn's Disease · Crohn's Disease (CD) · Moderately to Severely Active Ulcerative Colitis
Next primary completion
08 June 2027 · estimated
Open drug

Elritercept

Canonical investigational asset

6
Active trials
6
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Anemia · Cytopenia · Myelodysplastic Syndrome
Next primary completion
Not reported
Open drug

Mezagitamab

Canonical investigational asset

4
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 33
  • Phase 40
  • Phase not recorded0
Studied condition
Antibody-Mediated Rejection (AMR) · Immune Thrombocytopenic Purpura (ITP) · Kidney Disease
Next primary completion
Not reported
Open drug

TAK-360

Canonical investigational asset

4
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 23
  • Phase 31
  • Phase 40
  • Phase not recorded0
Studied condition
Idiopathic Hypersomnia · Narcolepsy Type 1 · Narcolepsy Type 2
Next primary completion
30 November 2026 · estimated
Open drug

Brentuximab vedotin

adcetris

3
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 22
  • Phase 30
  • Phase 41
  • Phase not recorded0
Studied condition
Hodgkin Disease · Hodgkin Lymphoma · Lymphoma
Next primary completion
Not reported
Open drug

78 of 127 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

6 selected programmes · accepted investigational links cover 78 of 127 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

Takeda trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
A Study of TAK-360 in Adults With Idiopathic Hypersomnia
TAK-360

NCT06812078

Phase 2 · Recruiting

Trial source and qualifications

A Study of TAK-360 in Adults With Idiopathic Hypersomnia

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 07 Feb 2025 · actual
    Primary completion: 30 Nov 2026 · estimated
    Study completion: 30 Nov 2026 · estimated

    2021202220232024202520262027202820292030
    A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)
    TAK-360

    NCT06952699

    Phase 2 · Recruiting

    Trial source and qualifications

    A Study of TAK-360 in Adults With Narcolepsy Without Cataplexy (NT2)

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

    3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    3 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 06 May 2025 · actual
      Primary completion: 30 Nov 2026 · estimated
      Study completion: 30 Nov 2026 · estimated

      2021202220232024202520262027202820292030
      A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy
      Oveporexton

      NCT07363720

      Phase 3 · Active, not recruiting

      Trial source and qualifications

      A Trial of TAK-861 for the Treatment of Narcolepsy With Cataplexy

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      4 candidate observations · 3 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • enrollment change · Recorded 2026-09-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • status flip · Recorded 2026-09-02 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • pc date moved · Recorded 2026-10-31 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 29 Jan 2026 · actual
      Primary completion: 17 Dec 2026 · estimated
      Study completion: 17 Dec 2026 · estimated

      2021202220232024202520262027202820292030
      A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)
      Maribavir

      NCT05319353

      Phase 3 · Recruiting

      Trial source and qualifications

      A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Cytomegalovirus (CMV) Infection in Children and Adolescents Who Have Received a Hematopoietic Stem Cell Transplant (HSCT) or a Solid Organ Transplant (SOT)

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

      2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      2 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 13 Nov 2023 · actual
        Primary completion: 18 Jan 2027 · estimated
        Study completion: 18 Jan 2027 · estimated

        2021202220232024202520262027202820292030
        A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
        Teduglutide

        NCT06973304

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

        3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        1 inspected observations omitted. At most three verified observations are shown, not full history.

        • enrollment change · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
        • status flip · Recorded 2026-09-09 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 26 Jun 2025 · actual
        Primary completion: 10 Feb 2027 · estimated
        Study completion: 28 Jul 2027 · estimated

        2021202220232024202520262027202820292030
        A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease
        Zasocitinib

        NCT06233461

        Phase 2 · Recruiting

        Trial source and qualifications

        A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

        1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        Up to three verified eligible observations in the bounded history window.

        • pc date moved · Recorded 2026-08-27 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

        Start: 05 Mar 2024 · actual
        Primary completion: 17 Feb 2027 · estimated
        Study completion: 23 Jul 2027 · estimated

        2021202220232024202520262027202820292030

        Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

        6 selected of 56 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 8 actual primary completions, 0 untyped primary completions, 0 past estimates, 4 outside the horizon, 0 contradictory dates.

        04 / Therapeutic focus

        Where the activity is

        23

        active trials in Immunology & Inflammation

        Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

        Active trials by primary therapeutic area

        • Immunology & Inflammation23 trials
        • Oncology23 trials
        • Neurology10 trials
        • Haematology7 trials
        • Dermatology5 trials
        • Infectious Disease4 trials
        • Gastroenterology & Hepatology2 trials
        • Metabolic/Endocrine/Nutrition1 trials
        • Psychiatry & Addiction1 trials
        • Renal & Urology1 trials
        • Unmapped50 trials
        • Healthy volunteers0 trials

        Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

        06 / Related companies

        All companies
        P

        Pfizer

        Shared indexed programme context · 1 selected asset

        Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

        Sources, scope and methodology

        ClinicalTrials.gov lead-sponsor scope

        Canonical current-owner attribution covers 1,745 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: Takeda. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

        ClinicalTrials.gov

        Attribution coverage

        1,749 distinct registry candidates produced 1,745 accepted studies. 0 mapped to other owners, 4 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 0 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

        Indexed enrichment

        1,409 scoped records have indexed enrichment and 336 do not. Missing enrichment does not remove a trial from cohort counts.

        Scope observation

        The successful attribution check completed at 2026-11-01T04:09:50.355Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot 01bbd62ca76097605581f498dd77c8bc66e8bdce4a64885b6b433da85544b223.

        Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

        Dated canonical-attribution snapshot: 1,745 mapped lead-sponsored clinical studies across all statuses. 1,409 have indexed enrichment, 336 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

        Keep following
        what matters.

        Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

        Build your watch

        Choose what to track in the watch builder.